Brian Woodfall

2.5k total citations
29 papers, 1.9k citations indexed

About

Brian Woodfall is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Brian Woodfall has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 21 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Brian Woodfall's work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (9 papers). Brian Woodfall is often cited by papers focused on HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (9 papers). Brian Woodfall collaborates with scholars based in United States, United Kingdom and France. Brian Woodfall's co-authors include Monika Peeters, Goedele De Smedt, Johan Vingerhoets, Richard M. W. Hoetelmans, Richard Haubrich, Thomas N. Kakuda, Christine Katlama, Jacob Lalezari, Monika Schöller‐Gyüre and Beatriz Grinsztejn and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Brian Woodfall

29 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Woodfall United States	20	1.8k	1.4k	363	208	186	29	1.9k
Susan L. Ford United States	22	1.5k 0.8×	1.1k 0.8×	391 1.1×	215 1.0×	166 0.9×	56	1.8k
Johan Vingerhoets United States	22	2.4k 1.4×	2.1k 1.5×	556 1.5×	176 0.8×	318 1.7×	46	2.6k
Prudence Ive South Africa	22	1.7k 0.9×	950 0.7×	702 1.9×	176 0.8×	99 0.5×	48	2.0k
Trevor Hawkins United States	17	992 0.6×	726 0.5×	368 1.0×	223 1.1×	191 1.0×	29	1.5k
George J. Hanna United States	29	2.6k 1.5×	2.4k 1.8×	456 1.3×	434 2.1×	231 1.2×	77	3.1k
Joseph Quinn United States	11	1.3k 0.7×	1.0k 0.8×	351 1.0×	171 0.8×	96 0.5×	14	1.6k
Marshall W. Fordyce United States	16	1.5k 0.8×	955 0.7×	443 1.2×	500 2.4×	179 1.0×	30	1.8k
Scott C. Brun United States	15	1.5k 0.8×	1.4k 1.0×	183 0.5×	392 1.9×	84 0.5×	16	1.8k
Erin Quirk United States	19	1.6k 0.9×	1.2k 0.9×	277 0.8×	605 2.9×	181 1.0×	42	1.8k
Martin S. Rhee United States	21	1.3k 0.7×	1000 0.7×	298 0.8×	387 1.9×	123 0.7×	53	1.5k

Countries citing papers authored by Brian Woodfall

Since Specialization

Citations

This map shows the geographic impact of Brian Woodfall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Woodfall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Woodfall more than expected).

Fields of papers citing papers by Brian Woodfall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Woodfall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Woodfall. The network helps show where Brian Woodfall may publish in the future.

Co-authorship network of co-authors of Brian Woodfall

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Woodfall. A scholar is included among the top collaborators of Brian Woodfall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Woodfall. Brian Woodfall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meyer, Sandra De, Denisa Bojková, Jindřich Činátl, et al.. (2020). Lack of antiviral activity of darunavir against SARS-CoV-2. International Journal of Infectious Diseases. 97. 7–10. 95 indexed citations

Kakuda, Thomas N., Brian Woodfall, Tine De Marez, et al.. (2013). Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. Journal of Antimicrobial Chemotherapy. 69(3). 728–734. 11 indexed citations

Grinsztejn, Beatriz, Giovanni Di Perri, William Towner, et al.. (2010). A Review of the Safety and Tolerability Profile of the Next-Generation NNRTI Etravirine. AIDS Research and Human Retroviruses. 26(7). 725–733. 1 indexed citations

Yéni, Patrick, Anthony Mills, Monika Peeters, et al.. (2010). Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals. Current HIV Research. 8(7). 564–576. 2 indexed citations

Trottier, Benoît, Giovanni Di Perri, José Valdez Madruga, et al.. (2010). Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2. HIV Clinical Trials. 11(4). 175–185. 9 indexed citations

Schöller‐Gyüre, Monika, Thomas N. Kakuda, Goedele De Smedt, et al.. (2010). Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled Phase I study in adults. Clinical Therapeutics. 32(2). 328–337. 14 indexed citations

Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations

Vingerhoets, Johan, Lotke Tambuyzer, Hilde Azijn, et al.. (2010). Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 24(4). 503–514. 137 indexed citations

Cohen, Calvin, Daniel S Berger, Gary Blick, et al.. (2009). Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 23(3). 423–426. 23 indexed citations

10.

Katlama, Christine, Richard Haubrich, Jacob Lalezari, et al.. (2009). Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 23(17). 2289–2300. 148 indexed citations

11.

Kakuda, Thomas N., Monika Peeters, Chris Corbett, et al.. (2008). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2. 46th Annual Meeting. 5 indexed citations

12.

Schöller‐Gyüre, Monika, Wim van den Brink, Thomas N. Kakuda, et al.. (2008). Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers. The Journal of Clinical Pharmacology. 48(3). 322–329. 33 indexed citations

13.

Schöller‐Gyüre, Monika, Thomas N. Kakuda, Goedele De Smedt, et al.. (2008). A pharmacokinetic study of etravirine (TMC125) co‐administered with ranitidine and omeprazole in HIV–negative volunteers. British Journal of Clinical Pharmacology. 66(4). 508–516. 50 indexed citations

14.

Montaner, Joan, Patrick Yéni, Nathan Clumeck, et al.. (2008). Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose‐Ranging Study Involving Treatment‐Experienced Patients with HIV‐1 Infection. Clinical Infectious Diseases. 47(7). 969–978. 19 indexed citations

15.

Schöller‐Gyüre, Monika, Marta Boffito, Anton Pozniak, et al.. (2008). Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(10). 1215–1222. 35 indexed citations

16.

Kakuda, Thomas N., Cassy Workman, Keikawus Arastéh, et al.. (2008). Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antiviral Therapy. 13(5). 655–661. 27 indexed citations

17.

Ruxrungtham, Kiat, Francesca Conradie, Peré Domingo, et al.. (2008). Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227^*. HIV Medicine. 9(10). 883–896. 54 indexed citations

18.

Madruga, José Valdez, Pedro Cahn, Beatriz Grinsztejn, et al.. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 370(9581). 29–38. 403 indexed citations

19.

Goebel, F. D., Anton Pozniak, Elena Vinogradova, et al.. (2006). Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects. AIDS. 20(13). 1721–1726. 103 indexed citations

20.

Gazzard, Brian, Anton Pozniak, Schlomo Staszewski, et al.. (2003). An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 17(18). F49–F54. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact